Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT05345236
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05329025
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05309629
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of QLS31905 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT05278832
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05262413
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Phase 3
- Conditions
- Multiple MyelomaRecurrent or Refractory
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05236621
- Locations
- 🇨🇳
Foshan First People's Hospital, Foshan, Guangdong, China
🇨🇳Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05179317
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, Shangdong, China
🇨🇳Liaoning Cancer Hospital, Shenyang, Liaoning, China
A Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Solid Tumors
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 419
- Registration Number
- NCT05171790
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05150405
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 354
- Registration Number
- NCT05149924
- Locations
- 🇨🇳
The first Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath